TP53 and central nervous system cancer: Using the same in vivo approach of genes in human gliomas (i.e., HRASG12V and TP53–/–; cMYC overexpression; EGFRvIII and EGFR overexpression and CDKN2A–/–; NF1–/– and PTEN–/– and TP53–/–), cerebral organoids derived from human-induced pluripotent stem cells (hiPSCs) were modified in order to induce neoplastic organoids (Bian et al., 2018; Ogawa et al., 2018) (Figure 2F and Table 1).